Lakefront Biotherapeutics | GLPG - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
argenx SE USD 355M 74.62M 2026-03
AstraZeneca USD 5.06B 455M 2026-03
Biogen USD 554.3M 128.2M 2026-03
Genmab DKK 208M 60M 2025-12
Gilead Sciences USD 1.45B 326M 2026-03
GlaxoSmithKline GBP 2.12B 558M 2026-03
GRIFOLS EUR 281M 5.7M 2026-03
Hikma Pharmaceutical USD 288M 149M 2025-12
Incyte USD 328.1M 62.31M 2026-03
Merck EUR 1.52B 80M 2026-03
Neurocrine Biosciences USD 318.5M 16.7M 2026-03
Novartis USD 3.14B 296M 2026-03
Roche Holding CHF 7.28B 3.99B 2025-12
Sanofi EUR 2.33B 419M 2026-03
UCB EUR 1.47B 193M 2025-12
Vertex Pharmaceuticals USD 493.7M 6.7M 2026-03